Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense? (Q38312446)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053448%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053448%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053448%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Stefano Caruso

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053448%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Giuseppe Cicero

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053448%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Christian Rolfo

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053448%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

2

Viviana Bazan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053448%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Valeria Amodeo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053448%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Daniele Fanale

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053448%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Lavinia Insalaco

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053448%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Giuseppe Bronte

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053448%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Antonio Russo

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053448%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

English

0 references

publication date

22 September 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053448%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Therapeutic Targets

22 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053448%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053448%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053448%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

1249-1261

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053448%20AND%20SRC:MED&resulttype=core&format=json

Colorectal cancer screening in Europe

22 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Estimates of cancer incidence and mortality in Europe in 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

MicroRNAs: small RNAs with a big role in gene regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

MicroRNAs: genomics, biogenesis, mechanism, and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Thrombospondin-1 and angiotensin II inhibit soluble guanylyl cyclase through an increase in intracellular calcium concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Enhanced proliferation and migration of vascular smooth muscle cells in response to vascular injury under hyperglycemic conditions is controlled by beta3 integrin signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Endogenous thrombospondin-1 is not necessary for proliferation but is permissive for vascular smooth muscle cell responses to platelet-derived growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Counterbalancing forces: what is thrombospondin-1 doing in atherosclerotic lesions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Nitric oxide, VEGF, and VEGFR-2: interactions in activity-induced angiogenesis in rat skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Molecular interactions that confer latency to transforming growth factor-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Molecular basis for the induction of an angiogenesis inhibitor, thrombospondin-1, by 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Up-regulation of thrombospondin-1 gene by epidermal growth factor and transforming growth factor beta in human cancer cells--transcriptional activation and messenger RNA stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Down regulation of c-Myc and induction of an angiogenesis inhibitor, thrombospondin-1, by 5-FU in human colon cancer KM12C cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Inhibition of microRNA function by antimiR oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Efficient in vivo microRNA targeting of liver metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Thrombospondin-based antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

CD47 applies the brakes to angiogenesis via vascular endothelial growth factor receptor-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Blockade of thrombospondin-1-CD47 interactions prevents necrosis of full thickness skin grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Therapies using anti-angiogenic peptide mimetics of thrombospondin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206

Increasing Survival of Ischemic Tissue by Targeting CD47

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.832206